New Delhi: Max Healthcare has signed a Memorandum of Understanding (MoU) with the Tata Institute for Genetics and Society (TIGS) to integrate advanced genetic research with clinical practice.
The initiative aims to improve patient outcomes and advance personalised medicine in India.
A Collaborative Platform for Research and Training
The agreement establishes a framework for joint research, training, and knowledge exchange between the two institutions. Through this partnership, Max Healthcare and TIGS will work together on genomics-driven healthcare initiatives, including research on rare genetic diseases and neonatal care informed by genetic insights.
The collaboration also focuses on developing personalised treatment strategies based on individual genetic profiles. Both organisations will engage in conferences, workshops, and training programmes to promote interdisciplinary learning between clinicians and researchers.
Bridging Research and Clinical Application
As part of the partnership, Max Healthcare will provide clinical expertise and access to patient data, while TIGS will contribute its advanced genomics research capabilities. Together, they aim to translate scientific discoveries into clinical applications, particularly in the areas of haematology, oncology, and neonatal health.
The partnership represents a major step toward combining scientific innovation and clinical excellence to enhance precision healthcare in India.
